Management of post‐transplant lymphoproliferative disorders

Summary The post‐transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that are one of the most serious complications of bone marrow and solid organ transplants. Because these disorders are rare, there are no randomized trials from which to derive optimal treatment....

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2018-08, Vol.182 (3), p.330-343
Main Authors: DeStefano, Christin B., Desai, Sanjal H., Shenoy, Aarthi G., Catlett, Joseph P.
Format: Article
Language:English
Subjects:
Bone marrow
Bone marrow transplantation
cellular therapies
Clinical trials
Complications
Epstein-Barr Virus Infections - complications
Epstein‐Barr virus
Graft rejection
Hematology
Hematopoietic stem cells
Humans
Immune reconstitution
Immunocompromised Host
Immunoproliferative diseases
Immunosuppressive Agents - adverse effects
Lymphocytes
lymphoproliferative disease
Lymphoproliferative Disorders - diagnosis
Lymphoproliferative Disorders - etiology
Lymphoproliferative Disorders - immunology
Lymphoproliferative Disorders - therapy
Management
new drugs for lymphoma
Organ Transplantation - adverse effects
Posttransplant lymphoproliferative disorders
Prognosis
Risk Factors
transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The post‐transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that are one of the most serious complications of bone marrow and solid organ transplants. Because these disorders are rare, there are no randomized trials from which to derive optimal treatment. Management can be challenging and must balance the goal of PTLD eradication with the risks of graft rejection, graft‐versus‐host disease, further delays in immune reconstitution and life‐threatening infections, among others. This paper will provide a comprehensive review of PTLD following solid organ transplant and haematopoietic stem cell transplant with a focus on management. Included is a discussion of novel agents that are being studied in clinical trials and, when combined or sequenced with conventional therapy, have the potential to improve outcomes.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.15263